Immunovant Inc expected to post a loss of 43 cents a share - Earnings Preview

Immunovant

30/01/2024 13:53

* Immunovant Inc  IMVT.OQ   IMVT.O  is expected to show no
change
in quarterly revenue when it reports  results on February 1
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Immunovant Inc is for a
loss
of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Immunovant
Inc is
$51.00​, above​ its last closing price of $39.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.50       -0.47      -0.45     Beat    4.4
 Jun. 30 2023  -0.47       -0.45      -0.57     Missed  -27.7
 Mar. 31 2023  -0.45       -0.43      -0.46     Missed  -7.5​
 Dec. 31 2022  -0.40       -0.39      -0.49     Missed  -26.1
 ​​Sep.        -0.39       -0.39      -0.41     Missed  -4.8
 30 2022                                                
 Jun. 30 2022  -0.39       -0.40      -0.35     Beat    11.6​
 Mar. 31 2022  -0.35       -0.38      -0.41     Missed  -9.1
 Dec. 31 2021  -0.32       -0.33      -0.36     Missed  -9.9
 This summary was machine generated January 30 at 13:53 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)